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SIONS: The risk of AVB in SND patients is increased in cases
with AF history. The strategy of primary AAI implantation in
SND is cost-saving in patients with no history of AF but no such
proﬁt is observed in the group with the history of AF.
CARDIOVASCULAR
CARDIOVASCULAR—Quality of Life/Utility/Preference
Studies
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OBJECTIVES: The objective of our study was to assess 
depressive symptomatology (DS) among CVD affected women.
METHODS: Symptomatic women patients suffering from CVD
(CEAP C0 to C4), aged over 18, newly treated by their GP with
a phlebotropic drug were enrolled in the study. Every patient
completed a self-questionnaire including the CES-D scale at day
0, day three and seven. A score over 17 indicates a possible DS,
a score over 23 indicates a probable DS. RESULTS: This analy-
sis includes the ﬁrst 371 patients assessed at day 0, D3 and D7.
The mean age was 45.0 years old (SD = 11, n = 370). The mean
CES-D scores at day 0, D3 and D7, were respectively 14.9 (SD
= 10.2), 13.7 (SD = 8.9) and 12.8 (SD = 10.1). The results high-
light a possible DS in our population (score over 17) for 36.3%,
32.3% and 29.0% respectively at day 0, D3 and D7 (p < 0.01,
n = 328). Patients that have expressed a probable DS were 74 at
inclusion (22.0% of the population); they show a signiﬁcant
improvement of their status assessed by CES-D. From those 74
patients, only 50 still had a score over 23 at D3 and 46 at D7
showing a decrease of 37.8% of the number of patients express-
ing a probable DS (p < 0.0001, n = 74, matched test J0-J7).
CONCLUSIONS: In the study of Rield assessing depressive
symptoms in older women (age 65 to 75), 23.1% of women
reported high depressive symptoms (CES-D score over 16). CVD
result in psychological effects that seriously affect patients’ lives.
Following patient management and the use of a phlebotropic
drug the prevalence of DS decreased rapidly showing evidence
of the relevance of this management.
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OBJECTIVES: The objective of our study was to describe the
proﬁle of French women suffering from Chronic venous disease
(CVD). METHODS: Symptomatic women patients suffering
from CVD (CEAP clinical classes C0 to C4), aged over 18, newly
treated by their GP with a phlebotropic drug were enrolled in
the study. They completed a self-questionnaire including the SF-
12, the CES-D and the CIVIQ scales at day zero, day three and
seven. RESULTS: This analysis includes the ﬁrst 399 patients
assessed at inclusion. Mean age was 45.0 years old (SD = 11, n
= 370). A total of 65.7% have a professional activity, 32% prac-
tice sport, 33% are smokers, 78.4% gave birth already and 50%
are under oral contraceptive. A total of 9.1% wear compression
stockings. At inclusion (n = 374), MCS-12 and PCS-12 were
respectively 44.7 (SD = 10.6) and 46.4 (SD = 8.4); and the mean
CIVIQ score was 32.6 (SD = 1.1). Concerning the CES-D, the
mean score were 14.9 (SD = 10.2), the results highlighting a 
possible depressive symptomatology in 36.3% of our population
(score 17), and a probable depressive symptomatology in 22.0%
of our population (score 23). CONCLUSIONS: CVD has a great
impact on women. The SF-12 mean scores were below those of
the age- and gender-matched general population. Women with
CVD report greater risk of high depressive symptoms, compared
to the study of Rield where 23.1% of women did (CES-D score
16, age 65 to 75). The impact of CVD on patients daily life is
high even if it seems relative compared to the mean scores
obtained when initially validating the CIVIQ; for example for
patients suffering venous insufﬁciency of lower limb and arteri-
tis mean score was 53.08 (SD = 14.9), unfortunately compari-
son data with patients suffering CVD are lacking.
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OBJECTIVES: The objective of our study was to assess health
status among women suffering from CVD. METHODS: Symp-
tomatic women patients suffering from CVD (CEAP clinical
classes C0 to C4), aged over 18, newly treated by their GP with
a phlebotropic drug were enrolled in the study. Every patient
hadto complete a self-questionnaire including the SF-12 scale 
at day 0, day 3 and day 7. The SF-12 is a generic measure of
health statusThe SF-12 is composed of two dimensions, a Phys-
ical Component Summary (PCS-12) and a Mental component
Summary (MCS-12). The results are standardised on the general
US population (mean score of 50 (SD = 10)) so results for 1 can
be meaningfully compared with the other. The lower the score is
the worse is the impact on patients’ quality of life. RESULTS:
This analysis includes the ﬁrst 399 patients assessed at day 0,
day 3 and day 7. The mean age was 45.0 years old (SD = 11, n
= 370). At inclusion time (n = 374), MCS-12 and PCS-12 were
respectively 44.7 (SD = 10.6) and 46.4 (SD = 8.4): at day 3 and
day 7, these dimensions were respectively: D3: 46.5 (SD = 10.2)
and 46.2 (SD = 8.0) D7: 48.0 (SD = 10.3) and 46.2 (SD = 7.8).
For the mental dimension, the difference was statistically signif-
icant (p = 0.0001). CONCLUSIONS: These results suggest that
CVD has a great impact on women. The SF-12 mean scores were
below those of the age- and gender-matched general population.
The patient management and the use of a phlebotropic drug
demonstrated an improvement on the mental health status of the
patient and a decrease of the impact of pain interfering with
patients normal work.
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OBJECTIVES: The CAMPHOR is the ﬁrst patient-completed
instrument speciﬁc to Pulmonary Arterial Hypertension (PAH).
It consists of separate scales assessing Overall Symptoms (sub-
divided into Energy Level, Breathlessness and Mood sub-scales),
Physical Functioning and Quality of Life (QoL). We report 
ﬁndings from a validation study. METHODS: Patients were
recruited from Papworth Hospital, Cambridge, UK for a postal
survey. They completed the CAMPHOR and the Nottingham
Health Proﬁle (NHP) on the ﬁrst occasion, then two weeks later
completed the CAMPHOR and EQ-5D. Internal consistency was
